Palbociclib D8
Cat. No.：YN290486
| 产品名称: | Palbociclib D8 |
| CAS No.: | 1628752-83-9 |
| Chemical Name: | 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl-2,2,3,3,5,5,6,6-d8)-2-pyridinyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one |
| Synonyms: | PD 0332991 D8 |
| 分子量: | 455.58 |
| 分子式: | C₂₄H₂₁D₈N₇O₂ |
| SMILES: | O=C1N(C2=NC(NC3=NC=C(C=C3)N4C([2H])(C([2H])(NC([2H])(C4([2H])[2H])[2H])[2H])[2H])=NC=C2C(C)=C1C(C)=O)C5CCCC5 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Palbociclib D8 (PD 0332991 D8) 是 Palbociclib 的氘代物。Palbociclib 是一种选择性的口服活性的CDK4和CDK6抑制剂，IC50分别为 11 nM 和 16 nM。Palbociclib 有潜力用于 ER 阳性和 HER2 阴性乳腺癌的研究。 |
| IC50和靶点: | [{name:"Cdk4/cyclin D3:9 nM (IC50)"},{name: "Cdk4/cyclin D1:11 nM (IC50)"},{name: "Cdk6/cyclin D2:16 nM (IC50)"},{name: "DYRK1A:2000 nM (IC50)"},{name: "MAPK:8000 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Fry, D.W., Harvey, P.J., Keller, P.R., et al.Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMol. Cancer Ther.3(11),1427-1438(2004)
Finn, R.S., Dering, J., Conklin, D., et al.PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Res.11(5),1-13(2009)
Lee, Y., Dominy, J.E., Choi, Y.J., et al.Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progressionNature510(7506),547-551(2014)
